3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
102
Breast Neoplasms
80
Neoplasms
72
Melanoma
63
Neoplasm Metastasis
62
Leukemia, Myeloid, Acute
58
Ovarian Neoplasms
54
Lymphoma, Non-Hodgkin
53
Multiple Myeloma
51
Prostatic Neoplasms
50
Colorectal Neoplasms
50
Glioblastoma
48
Pancreatic Neoplasms
47
Lung Neoplasms
45
Recurrence
42
Carcinoma, Renal Cell
40
Squamous Cell Carcinoma of Head and Neck
37
Leukemia, Lymphocytic, Chronic, B-Cell
37
Triple Negative Breast Neoplasms
35
Myelodysplastic Syndromes
30
Lymphoma, Large B-Cell, Diffuse
28
Glioma
28
Stomach Neoplasms
27
Precursor Cell Lymphoblastic Leukemia-Lymphoma
27
Lymphoma, B-Cell
27
Brain Neoplasms
27
Lymphoma, Follicular
26
Endometrial Neoplasms
26
Lymphoma
25
Carcinoma, Hepatocellular
24
Interventions
vistusertib
1
olaparib
1
durvalumab
1
danvatirsen
1
adavosertib
1
AZD4547
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Active not recruiting
×
Muscle Invasive Bladder Cancer
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled